Procter & Gamble Hygiene and Health Care Limited (PGHH) Fair Value & Analysis
Consumer Defensive · IN · Market cap ₹289B
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 4 days ago
Share price −4.1% over the past month.
A strong business, but screening 42% overvalued on our models.
What matters now
- A high-quality business (quality 84/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case (₹6,037). The favourable scenario is already priced in.
- A fairly wide model range (₹3,145 to ₹6,037) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ₹8,365 – ₹17,553 · fair‑value band ₹3,145 – ₹6,037 · the ₹8,365 price screens above the ₹4,849 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Procter & Gamble Hygiene and Health Care Limited (PGHH) currently trades at ₹8,365, while our model-based Fair Value estimate is ₹4,849, implying the stock looks roughly 42.0% overvalued today. The Quality Score stands at 84/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Procter & Gamble Hygiene and Health Care Limited generated revenue of ₹42.9B at a net margin of 20.0%. Revenue declined 5.1% year over year. It earns a return on equity of 114.9%. The balance sheet holds a net cash position of ₹5.7B. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹3,145 (bear case) to ₹6,037 (bull case); at ₹8,365, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 41% below its 52-week high, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -53% fair-value upside, at -42%, PGHH screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (₹5,565) versus Asset-Based (₹155.52). Highest evidence: Growth DCF (80).
Notify me when PGHH reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 80 · Market factors (momentum, volatility) 33
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Procter & Gamble Hygiene and Health Care Limited manufactures and sells branded packaged fast-moving consumer goods in the feminine care and healthcare businesses in India and internationally. It operates through Health care Products and Hygiene Products segments.
Full company description
Procter & Gamble Hygiene and Health Care Limited manufactures and sells branded packaged fast-moving consumer goods in the feminine care and healthcare businesses in India and internationally. It operates through Health care Products and Hygiene Products segments. The company offers health care products, including ointments and creams, cough drops, and tablets; and hygiene products, such as feminine hygiene and other skin care hygiene products, as well as feminine care pads. It also provides baby care products comprising nappies, pants, and baby wipes; grooming products; laundry products; hair care products; home, personal and skin care, and oral products. The company sells its products under the Vicks, Whisper, Pampers, Ariel, Tide, Gillette, Head & Shoulders, Herbal Essences, Pantene, Ambi Pur, Oral-B, Olay, and Old Spice brands through mass merchandisers, as well as grocery, membership club, drug, department, and high frequency stores. The company was incorporated in 1964 and is based in Mumbai, India. Procter & Gamble Hygiene and Health Care Limited operates as a subsidiary of The Procter & Gamble Company.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Procter & Gamble Hygiene and Health Care Limited reported revenue of ₹42.8B in FY2026 versus ₹37.9B in FY2022, a compound +3.1%/yr. Reported net income was ₹8.6B in FY2026, compounding +10.4%/yr from FY2022.
of which total revenue +7.2 pp · buybacks/dilution +0.0 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
PGHH screens 42% overvalued. Compare with Unilever PLC →
Peer Group
Household & Personal Products · 249 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Household & Personal Products median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Unilever PLC ULN | 1,080 MXN | 973.58 MXN | -10% |
| Hindustan Unilever Limited HINDUNILVR | ₹2,063 | ₹789.46 | -62% |
| Essity AB ESSITYA | kr 276.50 | kr 250.02 | -10% |
| Godrej Consumer Products Limited GODREJCP | ₹936.90 | ₹367.64 | -61% |
| Marico Limited MARICO | ₹855.00 | ₹233.05 | -73% |
| APR Co 278470 | 397,000 KRW | 137,521 KRW | -65% |
| Dabur India Limited DABUR | ₹411.25 | ₹175.59 | -57% |
| PT Unilever Indonesia Tbk UNVR | 1,760 IDR | 1,928 IDR | +10% |
| Amorepacific Corporation 090430 | 135,700 KRW | 84,785 KRW | -38% |
| Colgate-Palmolive (India) Limited COLPAL | ₹2,005 | ₹945.90 | -53% |
Compare Procter & Gamble Hygiene and Health Care Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Procter & Gamble Hygiene and Health Care Limited (PGHH) overvalued or undervalued?
What is the fair value of PGHH?
What is the quality score of PGHH?
What is the revenue of Procter & Gamble Hygiene and Health Care Limited (PGHH)?
What is the net profit margin of PGHH?
Does Procter & Gamble Hygiene and Health Care Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Procter & Gamble Hygiene and Health Care Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.